Genes/pathways expressed in non-GCB-subtype DLBCL showed similarity to those in ABC-subtype DLBCL [49], and the activation of Janus kinase (JAK)/signal transduction and activation of transcription factor 3 (STAT3) signaling might favor the constitutive expression of PD-L1 [50]. The gene discussed is TCF3; the disease is diffuse large B-cell lymphoma.